Skip to main content
  • Researchers to study COVID-19 vaccine efficacy and safety in transplant patients

    A national research study has just launched to investigate the effectiveness and safety of COVID-19 vaccines in transplant recipients. The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing over $2.84 million in this research study, based at University Health Network and called PREVenT COVID, short for Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients : A National Strategy.

  • Japan becomes first country to approve Ronapreve for COVID-19

    Roche announced that Japans Ministry of Health, Labour and Welfare has approved Ronapreve  casirivimab and imdevimab, for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act.

  • Oxford COVID19 vaccine may generate long term immune system responses, says study

    Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

    Writing in the journal Nature Immunology, they detail an investigation into one of the key features of adenovirus vaccines – their ability to generate strong and sustained populations of the ‘killer’ T-cell element of the immune system.

  • WHO recommends IL6 receptor blockers for COVID-19

    The World Health Organization (WHO) has updated its patient care guidelines to include interleukin-6 receptor blockers, a class of medicines that are lifesaving in patients who are severely or critically ill with COVID-19, especially when administered alongside corticosteroids.

    These were the findings from a prospective and a living network meta-analysis initiated by WHO, the largest such analysis on the drugs to date. Data from over 10 000 patients enrolled in 27 clinical trials were considered.

  • Two more Central Drug Laboratories at Pune and Hyderabad for Covid Vaccine Testing

    In the wake of the COVID-19 pandemic, and considering the enhanced production of COVID Vaccines, the Government proactively took the decision of setting up additional laboratories,to facilitate expedited testing / pre-release certification of the  vaccines.

  • COVID-19 aggravates antibiotic misuse in India

    The COVID-19 catastrophe in India has resulted in more than 30 million people infected with the virus and nearly 400,000 deaths, though experts are concerned that the figures most likely are much higher. Meanwhile, another public health crisis has emerged along with COVID-19: the widespread misuse of antibiotics.

  • The viruses can kill cancer cells, unveils good viruses concept

    Researchers from the Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the LIH Department of Oncology (DONC) are working on the development of novel anticancer strategies based on oncolytic viruses, “good” viruses that can specifically infect, replicate in and kill cancer cells. In particular, the LOVIT team elucidated the mechanism through which the H-1PV cancer-destroying virus can attach to and enter cancer cells, thereby causing their lysis and death.

  • Life Sciences recruitment at PGIMER, Salary upto Rs 50,000/- pm

    The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

    Recruitment of Research Staff for RESEARCH PROJECT: “A systematic and living evidence and guideline recommendation map on COVID-19” (RecMap Project)

  • CSIR and Tata MD partners to augment COVID-19 testing

    The Council for Scientific and Industrial Research (CSIR), and Tata Medical and Diagnostics Ltd (Tata MD), the new healthcare venture from the Tata Group have teamed up to boost the COVID-19 testing capacity across Tier-II and Tier-III towns as well as rural areas, across India. The two organisations are developing capacity to handle any future surge in the COVID-19 testing requirements.

  • Anti-COVID drug Colchicine cleared for phase 2 clinical trials

    Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd., Hyderabad, have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients.

    admin Fri, 06/18/2021 - 16:23
Subscribe to COVID-19

Search this website